2011
DOI: 10.1038/npp.2011.287
|View full text |Cite
|
Sign up to set email alerts
|

Csnk1e Is a Genetic Regulator of Sensitivity to Psychostimulants and Opioids

Abstract: Csnk1e, the gene encoding casein kinase 1-epsilon, has been implicated in sensitivity to amphetamines. Additionally, a polymorphism in CSNK1E was associated with heroin addiction, suggesting that this gene may also affect opioid sensitivity. In this study, we first conducted genome-wide quantitative trait locus (QTL) mapping of methamphetamine (MA)-induced locomotor activity in C57BL/6J (B6) Â DBA/ 2J (D2)-F 2 mice and a more highly recombinant F 8 advanced intercross line. We identified a QTL on chromosome 15… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

7
64
3

Year Published

2012
2012
2017
2017

Publication Types

Select...
7
1
1

Relationship

1
8

Authors

Journals

citations
Cited by 57 publications
(74 citation statements)
references
References 58 publications
7
64
3
Order By: Relevance
“…A further limitation of existing pharmacological studies is that the contribution of specific CK-1 isoforms to these drug-induced behaviors is unknown. Current evidence suggests that CSNK1D could normally serve to facilitate drug-induced behaviors whereas CSNK1E could normally serve to inhibit them (Bryant et al ., 2009a, Bryant et al ., 2012, Zhou et al ., 2010). Pharmacological inhibition with a CSNK1E-preferring compound increased psychostimulant and opioid activity and genetic knockout of Csnk1e increased psychostimulant-induced locomotor activity (Bryant et al ., 2009a, Bryant et al ., 2012), which is consistent with a negative regulatory role for the epsilon isoform in acute drug sensitivity.…”
Section: Introductionmentioning
confidence: 99%
“…A further limitation of existing pharmacological studies is that the contribution of specific CK-1 isoforms to these drug-induced behaviors is unknown. Current evidence suggests that CSNK1D could normally serve to facilitate drug-induced behaviors whereas CSNK1E could normally serve to inhibit them (Bryant et al ., 2009a, Bryant et al ., 2012, Zhou et al ., 2010). Pharmacological inhibition with a CSNK1E-preferring compound increased psychostimulant and opioid activity and genetic knockout of Csnk1e increased psychostimulant-induced locomotor activity (Bryant et al ., 2009a, Bryant et al ., 2012), which is consistent with a negative regulatory role for the epsilon isoform in acute drug sensitivity.…”
Section: Introductionmentioning
confidence: 99%
“…Several mouse genetic resources have been employed for the study of addiction including the BXD recombinant inbred strains (Belknap and Crabbe 1992; Belknap et al 1993; Crabbe et al 1994; Gallaher et al 1996; Grisel et al 1997; Kest et al 2004; Philip et al 2010; Phillips et al 1998; Roberts et al 1995; Tarantino et al 1998), F 2 hybrid crosses (Bergeson et al 2001; Doyle et al 2008; Ferraro et al 2005; Kest et al 2004), the Hybrid Mouse Diversity Panel (Bryant et al 2012a; Ghazalpour et al 2012; Park et al 2011; Parker et al 2012a), and advanced intercross lines (Bryant et al 2012b; Parker et al 2012a; Parker et al 2012b; Samocha et al 2010). While these resources have enabled substantial progress in the understanding of mechanisms underlying the effects of addictive drugs, each has some limitations in power, precision, genetic diversity, and genetic architecture.…”
Section: Discussionmentioning
confidence: 99%
“…Mice were 2-3 months of age on the first day of behavioral testing (F 2 range was 53-71 days; AIL range was 50-76 days). All mice went through an identical testing sequence: first, we measured open field (OF) behavior as part of a locomotor testing paradigm (Bryant et al 2012); 1 week later, we began the conditioned fear (CF) paradigm. All experiments were performed in accordance with the National Institutes of Health guidelines for care and use of laboratory animals.…”
Section: Behavioral Testingmentioning
confidence: 99%